Human PLK1 / PLK-1

Rabbit

Human (tested or 100% immunogen sequence identity)

IgG Polyclonal

Unconjugated

Affinity purified

Unmodified

Anti-Polo-like Kinase pT210 Antibody was produced by repeated immunizations with a synthetic phospho peptide corresponding to an internal region near aa 200-225 of Human Polo-like kinase 1 (Plk1) protein.

pThr210

This antibody was affinity purified. This antibody is specific for phosphorylated human Plk-1 protein at the pT210 residue. BLAST analysis indicates 100 % homology of the immunizing sequence with Plk-1 homologues from human, chimpanzee, pig, chicken, mouse, rat, Xenopus, dog, mosquito, zebra fish, starfish, sea urchin and fruit fly. Cross reactivity with Plk-1 protein homologues from C.elgans and honeybee may also occur as sequence homology varies by one amino acid residue in this sequence. Reactivity with Plk-1 protein from other sources is not known. Minimal reactivity is expected with the non-phosphorylated form of the protein.

• IHC
• IHC - Paraffin (10 µg/ml)
• Western blot (1:200 - 1:2000)
• ELISA (1:3000 - 1:12000)

Immunohistochemistry: LS-B50 was validated for use in immunohistochemistry on a panel of 21 formalin-fixed, paraffin-embedded (FFPE) human tissues after heat induced antigen retrieval in pH 6.0 citrate buffer. After incubation with the primary antibody, slides were incubated with biotinylated secondary antibody, followed by alkaline phosphatase-streptavidin and chromogen. The stained slides were evaluated by a pathologist to confirm staining specificity. The optimal working concentration for LS-B50 was determined to be 10 ug/ml.Western Blot: It is suggested to use a nuclear extract from synchronized cells to greatly increase the abundance of this protein in preparations.

0.02 M Potassium Phosphate, pH 7.2, 0.15 M NaCl, 0.01% Sodium Azide

Store at 4°C or -20°C. Avoid freeze-thaw cycles.

For research use only. Intended for use by laboratory professionals.

This antibody carries the LSBio 100% Guarantee.

Uniprot: P53350 NCBI: NM_005030 NP_005021.2